Sean Proehl - Dermata Therapeutics Senior Development
| DRMA Stock | USD 1.13 0.03 2.73% |
Executive
Sean Proehl is Senior Development of Dermata Therapeutics
| Address | 3525 Del Mar Heights Road, San Diego, CA, United States, 92130 |
| Phone | 858 800 2543 |
| Web | https://www.dermatarx.com |
Dermata Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.9068) % which means that it has lost $0.9068 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7301) %, meaning that it created substantial loss on money invested by shareholders. Dermata Therapeutics' management efficiency ratios could be used to measure how well Dermata Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 30, 2024, Return On Tangible Assets is expected to decline to -1.03. In addition to that, Return On Capital Employed is expected to decline to -1.33. At present, Dermata Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 5.53, whereas Total Assets are forecasted to decline to about 6.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| John Cavan | Hepion Pharmaceuticals | 66 | |
| David Marks | Immix Biopharma | N/A | |
| MD FFPM | Immix Biopharma | 64 | |
| Gary Whale | Zura Bio Limited | 50 | |
| Kiran MBBS | Zura Bio Limited | 51 | |
| Gael Hedou | Sonnet Biotherapeutics Holdings | 52 | |
| Michael Howell | Zura Bio Limited | 47 | |
| Khullani JD | Cardio Diagnostics Holdings | 40 | |
| Stephen McAndrew | Sonnet Biotherapeutics Holdings | 70 | |
| David Brady | Zura Bio Limited | N/A | |
| Ben JD | Immix Biopharma | N/A | |
| John SullivanBolyai | Hepion Pharmaceuticals | 76 | |
| MHS MD | Windtree Therapeutics | 65 | |
| Gerhard Bauer | Immix Biopharma | N/A | |
| Linda Mahoney | Phio Pharmaceuticals Corp | N/A | |
| Kimberly Davis | Zura Bio Limited | 56 | |
| Patrick Mayo | Hepion Pharmaceuticals | N/A | |
| Theresa Lowry | Zura Bio Limited | 50 | |
| Sandra Vedrick | Revelation Biosciences | N/A | |
| George Cox | Windtree Therapeutics | 72 | |
| Daniel Trepanier | Hepion Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -1.73 | ||||
| Return On Asset | -0.91 |
Dermata Therapeutics Leadership Team
Elected by the shareholders, the Dermata Therapeutics' board of directors comprises two types of representatives: Dermata Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dermata. The board's role is to monitor Dermata Therapeutics' management team and ensure that shareholders' interests are well served. Dermata Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dermata Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Maria MBA, Senior Assurance | ||
| Gerald Proehl, President, Founder | ||
| Sean Proehl, Senior Development | ||
| David Hale, CoFounder Director | ||
| Dr MPH, Senior Officer |
Dermata Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dermata Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.73 | ||||
| Return On Asset | -0.91 | ||||
| Current Valuation | (3.9 M) | ||||
| Shares Outstanding | 2.04 M | ||||
| Shares Owned By Insiders | 0.84 % | ||||
| Shares Owned By Institutions | 0.66 % | ||||
| Number Of Shares Shorted | 90.16 K | ||||
| Price To Book | 0.47 X | ||||
| EBITDA | 247.22 K | ||||
| Net Income | (7.79 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Dermata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dermata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dermata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dermata Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dermata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. If investors know Dermata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dermata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (13.36) | Return On Assets (0.91) | Return On Equity (1.73) |
The market value of Dermata Therapeutics is measured differently than its book value, which is the value of Dermata that is recorded on the company's balance sheet. Investors also form their own opinion of Dermata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dermata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dermata Therapeutics' market value can be influenced by many factors that don't directly affect Dermata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dermata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dermata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.